Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 13/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamic Acid SCHEMBL4872027 | 0.93 | AOC3 (0.37) | AOC3GAAUSP28 | |
| Hydrochloric Acid SCHEMBL6390888 | 0.92 | ALDH1A1 (0.39) | ALDH1A1AOC3FKBP1ATSHRUSP28 | |
| Carbamic Acid SCHEMBL4875824 | 0.90 | GAA (0.44) | ALDH1A1GAALMNATSHR | |
| SCHEMBL14019596 | 0.86 | ALDH1A1 (0.40) | ALDH1A1AOC3GAALMNAFKBP1A | |
| Hydrochloric Acid SCHEMBL4873611 | 0.86 | ALDH1A1 (0.40) | ALDH1A1AOC3GAALMNAFKBP1A | |
| Carbamic Acid SCHEMBL4871746 | 0.85 | AOC3 (0.39) | AOC3 | |
| Carbamic Acid SCHEMBL5670031 | 0.84 | AOC3 (0.43) | AOC3 | |
| Carbamic Acid SCHEMBL4990503 | 0.84 | AOC3 (0.41) | AOC3 | |
| SCHEMBL4874627 | 0.83 | ALDH1A1 (0.39) | ALDH1A1AOC3GAALMNAFKBP1A | |
| Carbamic Acid SCHEMBL4870742 | 0.83 | AOC3 (0.39) | AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608365-B1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | R TECH UENO LTD (JP) | 2013-10-02 | — | — | EP | disclosed |
| US-7442715-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2008-10-28 | — | — | US | disclosed |
| US-20060276521-A1 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-12-07 | — | — | US | disclosed |
| US-7125901-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-10-24 | — | — | US | disclosed |
| US-20060128770-A1 | Thiazole derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276521-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | ALDH1A1 930/4885AOC3 782/4885GAA 4431/4885 |
| US-20060128770-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | ALDH1A1 930/4885AOC3 782/4885GAA 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.